Published in J Endocrinol on December 01, 2004
Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition. Chem Rev (2008) 2.65
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology (2007) 1.51
Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest (2008) 1.38
Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol (2005) 1.30
Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology (2009) 1.27
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
MEPE expression in osteocytes during orthodontic tooth movement. Arch Oral Biol (2007) 1.11
Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone (2012) 1.07
Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J Bone Miner Metab (2011) 1.06
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr (2012) 1.03
MEPE is a novel regulator of growth plate cartilage mineralization. Bone (2012) 1.01
Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest (2008) 0.96
The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled. Cell Biochem Funct (2012) 0.96
Expression and processing of small integrin-binding ligand N-linked glycoproteins in mouse odontoblastic cells. Arch Oral Biol (2008) 0.95
Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol (2008) 0.93
ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol (2010) 0.92
MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One (2013) 0.91
Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol (2010) 0.86
Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. Pediatr Nephrol (2006) 0.85
Identification of novel regulators of osteoblast matrix mineralization by time series transcriptional profiling. J Bone Miner Metab (2013) 0.84
Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X-linked hypophosphatemia. Periodontol 2000 (2013) 0.82
PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism. PLoS One (2014) 0.81
Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A (2008) 0.80
SPR4-peptide alters bone metabolism of normal and HYP mice. Bone (2014) 0.80
Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif. Bone (2015) 0.80
Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system. Adv Chronic Kidney Dis (2011) 0.77
1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression. J Bone Miner Res (2016) 0.76
Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: identification as an allele of 'Hyp'. J Biomed Sci (2011) 0.76
Advancing our understanding of osteocyte cell biology. Ther Adv Musculoskelet Dis (2009) 0.76
Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice. PLoS Biol (2016) 0.75
Phosphatonins: new hormones involved in numerous inherited bone disorders. Clin Cases Miner Bone Metab (2011) 0.75
Downregulation of PHEX in multibacillary leprosy patients: observational cross-sectional study. J Transl Med (2015) 0.75
Regulatory roles of miRNA-758 and matrix extracellular phosphoglycoprotein in cervical cancer. Exp Ther Med (2017) 0.75
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun (2001) 3.46
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem (2003) 2.91
MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics (2000) 2.75
Octreotide therapy for tumor-induced osteomalacia. N Engl J Med (2001) 2.19
Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem (2002) 2.12
Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva. J Biol Chem (1977) 1.89
Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res (2002) 1.84
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet (1997) 1.69
Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab (1995) 1.66
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet (1997) 1.64
Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics (2001) 1.60
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem (2000) 1.52
Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int (2001) 1.42
Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun (2002) 1.41
Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol (1998) 1.37
Salivary statherin. Dependence on sequence, charge, hydrogen bonding potency, and helical conformation for adsorption to hydroxyapatite and inhibition of mineralization. J Biol Chem (1992) 1.33
Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol (2002) 1.32
The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med (2004) 1.28
Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol (1996) 1.25
A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface. Proc Natl Acad Sci U S A (1998) 1.25
Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab (2004) 1.18
Inhibition of calcium phosphate precipitation by human salivary statherin: structure-activity relationships. Calcif Tissue Int (1992) 1.06
The location and nature of calcium-binding sites in salivary acidic proline-rich phosphoproteins. J Biol Chem (1981) 1.03
Refining the genetic map for the region flanking the X-linked hypophosphataemic rickets locus (Xp22.1-22.2). Hum Genet (1994) 1.02
Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab (2004) 1.02
Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J Bone Miner Res (1999) 1.01
Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab (2001) 1.00
The gene for X-linked hypophosphataemic rickets maps to a 200-300kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum Genet (1996) 0.96
Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse. Kidney Int (1996) 0.93
Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts. Bone (2004) 0.89
Hypophosphatemic rickets. Endocr Dev (2003) 0.89
The role of the PHEX gene (PEX) in families with X-linked hypophosphataemic rickets. Curr Opin Nephrol Hypertens (1998) 0.88
Dual action of phosphonoformic acid on Na(+)-phosphate cotransport in opossum kidney cells. Am J Physiol (1992) 0.88
Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol (1988) 0.87
Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport. Gen Pharmacol (1996) 0.86
Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells. J Endocrinol (2001) 0.85
Phosphate wasting in oncogenic osteomalacia: PHEX is normal and the tumor-derived factor has unique properties. Bone (2001) 0.84
Phosphonoformic acid blunts adaptive response of renal and intestinal Pi transport. Am J Physiol (1993) 0.84
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Association of maternal vitamin D status during pregnancy with bone-mineral content in offspring: a prospective cohort study. Lancet (2013) 5.28
Quality of care, risk management, and technology in obstetrics to reduce hospital-based maternal mortality in Senegal and Mali (QUARITE): a cluster-randomised trial. Lancet (2013) 2.88
Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ (2004) 2.59
Effect on birth outcomes of a formalised approach to care in hospital labour assessment units: international, randomised controlled trial. BMJ (2008) 2.11
Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. Obstet Gynecol (2006) 2.08
An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol (2010) 1.90
A cis-acting control region is required exclusively for the tissue-specific imprinting of Gnas. Nat Genet (2004) 1.81
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med (2013) 1.77
Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res (2010) 1.73
Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet (2010) 1.58
Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology (2007) 1.51
Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res (2008) 1.49
Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol (2002) 1.47
Abnormal fetal heart rate tracing patterns in patients with thick meconium staining of the amniotic fluid: association with perinatal outcomes. Am J Obstet Gynecol (2008) 1.46
Twin-twin transfusion syndrome: an ethics-based and evidence-based argument for clinical research. Am J Obstet Gynecol (2010) 1.44
Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) (2003) 1.43
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control (2011) 1.43
Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun (2002) 1.41
The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem (2007) 1.40
Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab (2012) 1.39
Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr (2005) 1.30
Effect of potassium citrate supplementation or increased fruit and vegetable intake on bone metabolism in healthy postmenopausal women: a randomized controlled trial. Am J Clin Nutr (2008) 1.29
Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) (2010) 1.28
Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology (2009) 1.27
Risk factors for variation in 25-hydroxyvitamin D₃ and D₂ concentrations and vitamin D deficiency in children. J Clin Endocrinol Metab (2012) 1.22
Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer (2009) 1.21
Congenital hyperinsulinism. Early Hum Dev (2010) 1.21
Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. Hypertension (2010) 1.20
Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet (2011) 1.20
Attitudes of the new generation of Canadian obstetricians: how do they differ from their predecessors? Birth (2011) 1.19
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone (2009) 1.17
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res (2011) 1.14
The effects of vitamin D(3) supplementation on serum total 25[OH]D concentration and physical performance: a randomised dose-response study. Br J Sports Med (2013) 1.13
The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol (2007) 1.13
High-dose vs low-dose oxytocin for labor augmentation: a systematic review. Am J Obstet Gynecol (2010) 1.11
Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med (2009) 1.08
Maternal and fetal leptin, adiponectin levels and associations with fetal insulin sensitivity. Obesity (Silver Spring) (2013) 1.07
Maternal glucose tolerance in pregnancy affects fetal insulin sensitivity. Diabetes Care (2010) 1.07
Impact of pregnancy-induced hypertension on birthweight by gestational age. Paediatr Perinat Epidemiol (2004) 1.05
Is there a potential therapeutic value of copper and zinc for osteoporosis? Proc Nutr Soc (2002) 1.04
History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol (2002) 1.04
The effect of posture and positive pressure breathing on the hemodynamics of the internal jugular vein. Aviat Space Environ Med (2003) 1.03
Cohort profile: the maternal-infant research on environmental chemicals research platform. Paediatr Perinat Epidemiol (2013) 1.03
Effect of fetal position on second-stage duration and labor outcome. Obstet Gynecol (2005) 1.02
Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet (2012) 1.02
Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer (2011) 1.01
MEPE's diverse effects on mineralization. Calcif Tissue Int (2009) 1.01
Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab (2005) 1.00
Analysis of the human hephaestin gene and protein: comparative modelling of the N-terminus ecto-domain based upon ceruloplasmin. Protein Eng (2002) 1.00
Maternal and fetal IGF-I and IGF-II levels, fetal growth, and gestational diabetes. J Clin Endocrinol Metab (2012) 0.99
Psychosocial stress in pregnancy and preterm birth: associations and mechanisms. J Perinat Med (2013) 0.99
Dietary silicon interacts with oestrogen to influence bone health: evidence from the Aberdeen Prospective Osteoporosis Screening Study. Bone (2011) 0.97
Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr (2005) 0.97
Vitamin D and pre-eclampsia: original data, systematic review and meta-analysis. Ann Nutr Metab (2014) 0.97
Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J Bone Miner Res (2005) 0.96
Low bone mineral density in men with chronic obstructive pulmonary disease. Respir Res (2011) 0.96
Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J Clin Invest (2010) 0.95
Prospective association of 25-hydroxyvitamin d3 and d2 with childhood lung function, asthma, wheezing, and flexural dermatitis. Epidemiology (2013) 0.95
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer (2007) 0.95
Glucose metabolism and neurological outcome in congenital hyperinsulinism. Semin Pediatr Surg (2011) 0.95
The effect of training status on the metabolic response of bone to an acute bout of exhaustive treadmill running. J Clin Endocrinol Metab (2010) 0.94
Characteristics of hearing impairment in Yemeni children with chronic suppurative otitis media: a case-control study. Int J Pediatr Otorhinolaryngol (2009) 0.94
Changes in bone mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic kidney disease stages. J Bone Miner Metab (2010) 0.93
Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol (2011) 0.93
ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol (2010) 0.92
Associations of 25-hydroxyvitamin D2 and D3 with cardiovascular risk factors in childhood: cross-sectional findings from the Avon Longitudinal Study of Parents and Children. J Clin Endocrinol Metab (2012) 0.91
MEPE/OF45 protects cells from DNA damage induced killing via stabilizing CHK1. Nucleic Acids Res (2009) 0.91
The surgical management of renal hyperparathyroidism. Eur Arch Otorhinolaryngol (2011) 0.91
Association of serum 25-hydroxyvitamin D₃ and D₂ with academic performance in childhood: findings from a prospective birth cohort. J Epidemiol Community Health (2012) 0.91
Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control (2012) 0.90
Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev (2009) 0.90
Effect on neonatal outcomes in gestational hypertension in twin compared with singleton pregnancies. Obstet Gynecol (2006) 0.90
The role of exercise intensity in the bone metabolic response to an acute bout of weight-bearing exercise. J Appl Physiol (1985) (2010) 0.90
Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease. J Bone Miner Res (2013) 0.89
A birth cohort study to investigate the association between prenatal phthalate and bisphenol A exposures and fetal markers of metabolic dysfunction. Environ Health (2014) 0.89
Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev (2013) 0.89
Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res (2010) 0.89
Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. J Bone Miner Res (2013) 0.88
Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab (2007) 0.88
Pregnancy-induced hypertension and perinatal mortality. J Reprod Med (2007) 0.87
Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem (2003) 0.87
Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J Bone Miner Res (2004) 0.87
The association of serum 25-hydroxyvitamin D3 and D2 with depressive symptoms in childhood--a prospective cohort study. J Child Psychol Psychiatry (2011) 0.87
Influence of vitamin D status on respiratory infection incidence and immune function during 4 months of winter training in endurance sport athletes. Exerc Immunol Rev (2013) 0.87
Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem (2003) 0.87
Maternal plasma 25-hydroxyvitamin D levels, angiogenic factors, and preeclampsia. Am J Obstet Gynecol (2013) 0.86
Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J Bone Miner Res (2007) 0.86
Ambient Heat and Sudden Infant Death: A Case-Crossover Study Spanning 30 Years in Montreal, Canada. Environ Health Perspect (2015) 0.86
Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. PLoS One (2013) 0.85
Medical care of obese children and adolescents. APV: a standardised multicentre documentation derived to study initial presentation and cardiovascular risk factors in patients transferred to specialised treatment institutions. Eur J Pediatr (2004) 0.85
Analysis of body composition in individuals with high bone mass reveals a marked increase in fat mass in women but not men. J Clin Endocrinol Metab (2013) 0.85
Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials (2013) 0.85
Association of uric acid with progression to preeclampsia and development of adverse conditions in gestational hypertensive pregnancies. Am J Hypertens (2012) 0.85
Standardization of vitamin D assays: art or science? Ann Clin Biochem (2009) 0.85